Background and Purpose: Vortioxetine, a multimodal‐acting antidepressant, has recently shown analgesic properties. We aimed to investigate its prophylactic effect in the osteoarthritis (OA) model and gain insights into the underlying molecular mechanisms. Duloxetine was studied as a reference.Experimental Approach: In the monoiodoacetate (MIA)‐induced rat model of knee OA, pain‐related behaviour was assessed in weight‐bearing and Von Frey tests. Antidepressants were administered orally once daily for 28 days. Gene expression of pain‐related mediators (Ngf, Il‐1β, Tnf‐α, Bdnf, and Tac1 encoding substance P) and oxidative stress parameters were determined after completion of the treatment/behavioural testing protocol.Key Results: Vortioxetine and duloxetine dose dependently reduced weight‐bearing asymmetry and mechanical hyperalgesia of the paw ipsilateral to the MIA‐injected knee. Vortioxetine reduced the increased Ngf mRNA expression in the MIA‐injected knees to the level in sham‐injected counterparts. It reduced oxidative stress parameters in the affected knees, more effectively in females than males. Duloxetine showed no effect on Ngf mRNA expression and oxidative stress. Both antidepressants decreased mRNA expression of pain‐related mediators in the lumbar L3–L5 ipsilateral DRGs and spinal cords, which were up‐regulated in MIA‐injected rats. This effect was male‐specific.Conclusion and Implications: Vortioxetine may be effective against the development of chronic pain in OA. Its antihyperalgesic effect may be mediated, at least in part, by normalization of NGF expression in the affected joint. Decrease of localized oxidative stress and of expression of pain‐related mediators that contribute to central sensitization are also involved in vortioxetine's antihyperalgesic effect, in a sex‐specific pattern.
Medication overuse headache (MOH) is a chronic secondary headache disorder caused by excessive use of analgesics for acute headache treatment, predominantly affecting women. It is associated with reduced quality of life and cognitive deficits. The drugs most strongly linked to the development of MOH are triptans and opioids. Although opioid use is discouraged in headache treatment, codeine, as a component of combined analgesic preparations (in Serbia and the surrounding region), is used relatively often. We aimed to establish a codeine-induced MOH model in female and male mice, and to assess pain-related behaviour, general well-being/motivation, and cognitive performance. MOH was induced by administering codeine (15 mg/kg/day p.o. for 10 days) to female and male C57BL/6 mice. Periorbital allodynia was assessed using von Frey test. Cognitive performance was evaluated using the novel object recognition test, and general well-being using the burrowing test. After 12 days of codeine withdrawal, we assessed the recurrence of periorbital allodynia induced by a low dose of glyceryl trinitrate (latent sensitisation phenomenon). Codeine caused a comparable level of periorbital allodynia in both sexes. After discontinuation of codeine, mechanical hypersensitivity gradually resolved in both males and females. Codeine reduced cognitive performance in both sexes, whereas burrowing activity was reduced only in codeine-treated females compared to the vehicle control group. Glyceryl trinitrate induced a recurrence of periorbital allodynia in both sexes, with a more pronounced effect in females. Codeine induced cutaneous allodynia and cognitive impairment in both sexes, whereas decreased motivation/general well-being and latent sensitisation were more pronounced in females.
Chronic migraine (CM) is a disabling disorder characterised by pain and cognitive impairment. Current preventive therapies show limited efficacy. GLP-1 receptor agonists (GLP-1RAs) exhibit antinociceptive and procognitive properties, yet the effects of the long-acting GLP-1RA dulaglutide remain unexamined. We assessed whether dulaglutide attenuates mechanical hypersensitivity and improves cognitive performance in a nitroglycerin-induced CM model, with focus on sex differences. CM was induced by repeated nitroglycerin injections (10 mg/kg, i.p., every other day over 9 days) in C57BL/6 mice of both sexes. Dulaglutide (30, 150 and 300 µg/kg/every 3 days, s.c.) and propranolol (20 mg/kg/day, i.p.; positive control) were administered throughout the protocol. Mechanical hypersensitivity was assessed by the von Frey test (VFT) and cognition by the novel object recognition test (NORT). Nitroglycerin induced basal and acute hypersensitivity, as well as cognitive deficits in both sexes (p < 0.05). In the VFT, dulaglutide reduced pain hypersensitivity (p < 0.05), comparably to propranolol. Sex differences appeared at the lowest and highest doses (p = 0.003, p = 0.013; respectively), with greater effects in females. In the NORT, dulaglutide (150 and 300 µg/kg) improved performance in both sexes (p < 0.05). Further analysis of the discrimination index revealed no significant sex differences (p > 0.05). Locomotor activity was unaffected. Taken together, dulaglutide reduced mechanical pain hypersensitivity and improved cognitive function without affecting locomotion in a CM model, supporting further investigation of dulaglutide in migraine prevention and associated cognitive disorders.
Epilepsy is a common brain disorder which frequently affects pediatric patients (from newborns to adolescents). The cornerstone of epilepsy treatment for most patients is the use of antiseizure medicines (ASM). These medications, when used as monotherapy or in combination, can achieve seizure control in up to 70% of patients with epilepsy. However, despite the availability of effective ASMs, adherence to these medicines in pediatric epilepsy tends to be suboptimal, which may adversely affect the long-term prognosis of pediatric patients. In this regard, pharmacist-led interventions, aimed at increasing the health literacy of patients and their family members regarding epilepsy treatment, have been shown to increase adherence to the prescribed ASMs. These interventions focus on educating patients and parents on the nature of epilepsy and practical aspects related to appropriate ASM use. In this article, we aimed to provide a useful source of information for pharmacists (and other healthcare workers) on how to counsel patients and parents on issues related to starting/using ASM treatment (e.g. appropriate dose titration, managing skipped doses), additional measures that may improve treatment outcomes (e.g. monitoring seizure frequency, avoidance of seizure triggers) and safety risks associated with ASMs (and how to control/mitigate these risks).
28 October 2026 in British Journal of Pharmacology
Background and Purpose: Chronic migraine (CM) is a highly disabling condition that remains suboptimally treated. Metabolic disturbances may trigger migraine chronification, whereas impaired endogenous pain inhibition contributes to CM development. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), used for type 2 diabetes and obesity, show efficacy in chronic pain models. We evaluated the prophylactic effects of liraglutide, semaglutide and dulaglutide compared with propranolol (reference drug), potential opioidergic/endocannabinoid involvement and sex differences in a CM model. Experimental Approach: Chronic migraine‐like hypersensitivity was induced by repeated nitroglycerin administration in male and female mice. The prophylactic effects of GLP‐1RAs and propranolol were examined using von Frey, acetone and orofacial glutamate tests. Body weight and glucose tolerance were monitored to evaluate metabolic safety. Potential opioidergic/endocannabinoid involvement in semaglutide‐induced antinociception (selected GLP‐1RA class representative) was assessed by pharmacological blockade and/or quantitative polymerase chain reaction (qPCR) analysis of pain‐related neurobiomarker mRNA expression in brainstem and trigeminal ganglia. Key Results: Liraglutide, semaglutide and dulaglutide dose‐dependently attenuated CM‐like hypersensitivity in both sexes, with efficacy comparable to propranolol. GLP‐1RAs did not affect metabolic parameters, whereas propranolol induced male‐specific hyperglycaemia. Semaglutide‐induced antinociception was partially sensitive to naloxone and was associated with sex‐dimorphic, brainstem‐specific transcriptional changes in opioid‐ and endocannabinoid‐related pathways. Semaglutide increased Glp1r, Cnr1 , Pomc, Pcsk1 and Pcsk2 mRNA expression in males, whereas it up‐regulated Glp1r and down‐regulated Faah and Mgll in females. Conclusions and Implications: GLP‐1RAs exert class‐wide antinociceptive effects in a preclinical CM model, with semaglutide‐based analyses suggesting sex‐specific modulation of central opioid‐ and endocannabinoid‐related pathways. These findings support further investigation of GLP‐1RAs as prophylactic strategies for migraine, particularly in individuals with metabolic comorbidities.